SERB To Buy Hansa Biopharma's Idefirix Rights In Europe, MENA For EUR 115 Mln
19/5 09:47
(RTTNews) - SERB Pharmaceuticals and Hansa Biopharma AB (HNSA.ST) announced Tuesday their agreement, under which SERB will acquire exclusive rights to develop and sell Hansa's kidney transplant drug Idefirix in Europe and the Middle East and North Africa or MENA region for 115 mi...